NRx Down After FDA Denies Breakthrough Therapy Designation

 NRx Pharmaceuticals Inc. shares were down 8%, to 53 cents, after the company said the U.S. Food and Drug Administration denied the Breakthrough Therapy designation request for Zyesami (aviptadil) for patients with Covid-19.

The stock declined 58% on May 26 after unfavorable results from a Zyesami study.

NRx has said it would evaluate options for Zyesami in protecting the lung in other respiratory disorders and in other therapeutic areas. NRx has focused on NRX-101 for treatment of severe bipolar depression in patients with acute suicidal ideation and behavior.

https://www.marketscreener.com/quote/stock/NRX-PHARMACEUTICALS-INC-38908842/news/NRx-Pharmaceuticals-Down-8-After-FDA-Denies-Breakthrough-Therapy-Designation-40711601/